ASH 2015 Complete Coverage

Idelalisib + Bendamustine, Rituximab: Important New Option for Relapsed/Refractory CLL

Idelalisib + Bendamustine, Rituximab: Important New Option for Relapsed/Refractory CLL

Idelalisib in combination with bendamustine and rituximab is superior to bendamustine and rituximab alone.

Venetoclax for Patients With Ultra-high Risk Relapsed/Refractory CLL

Venetoclax for Patients With Ultra-high Risk Relapsed/Refractory CLL

In "ultra-high risk" patients with chronic lymphocytic leukemia (CLL), treatment with venetoclax monotherapy resulted in a high overall response rate.

Phase 3 Trial Supports High-intensity Pretransplant Myeloablative Regimens for MDS, AML

Phase 3 Trial Supports High-intensity Pretransplant Myeloablative Regimens for MDS, AML

Results of a phase 3 randomized trial support high intensity conditioning prior to allogeneic stem cell transplantation as standard of care.

First-in-Human Trial CAR T Cell Trial Induces Multiple Myeloma Remissions

First-in-Human Trial CAR T Cell Trial Induces Multiple Myeloma Remissions

The first clinical trial of an anti-B-cell maturation antigen chimeric antigen receptor (CAR-BCMA) has shown strong anti-myeloma activity.

MRD Complete Response Induced by Blinatumomab Associated With Improved Survival

MRD Complete Response Induced by Blinatumomab Associated With Improved Survival

Minimal residual response (MRD) induced by blinatumomab montherapy was associated with longer survival and duration of response.

Adding Ixazomib to Lenalidomide Plus Dex Improves PFS in Myeloma

Adding Ixazomib to Lenalidomide Plus Dex Improves PFS in Myeloma

Adding ixazomib to lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma increased progression-free survival.

Ibrutinib Improves PFS vs IV Temsirolimus in Relapsed/Refractory Mantle Cell Lymphoma

Ibrutinib Improves PFS vs IV Temsirolimus in Relapsed/Refractory Mantle Cell Lymphoma

Ibrutinib is superior to temsirolimus for progression-free survival in patients with relapsed/refractory mantle cell lymphoma (MCL).

Brentuximab Vedotin Plus Bendamustine Active In Heavily Pretreated Hodgkin Lymphoma, ALCL

Brentuximab Vedotin Plus Bendamustine Active In Heavily Pretreated Hodgkin Lymphoma, ALCL

Combination of brentuximab vedotin with bendamustin is effective in Hodgkin lymphoma and anaplastic large T-cell lymphoma (ALCL).

EUTOS Survival Score Preferable for Chronic Myeloid Leukemia Prognosis

EUTOS Survival Score Preferable for Chronic Myeloid Leukemia Prognosis

For prognosis of long-term outcomes in chronic myeloid leukemia (CML), the European Treatment and Outcomes Study (EUTOS) score is recommended.

Obinutuzumab Plus Venetoclax Seems Tolerable in Elderly Patients with CLL, Coexisting Conditions

Obinutuzumab Plus Venetoclax Seems Tolerable in Elderly Patients with CLL, Coexisting Conditions

Obinutuzumab monotherapy for 1 cycle followed by venetoclax and obinutuzumab in elderly patients with chronic lymphocytic leukemia (CLL).

Ibrutinib Monotherapy Superior to Chlorambucil in Treatment-naïve Older Patients With CLL/SLL

Ibrutinib Monotherapy Superior to Chlorambucil in Treatment-naïve Older Patients With CLL/SLL

brutinib monotherapy was superior to chlorambucil with regard to survival and hematologic improvement.

Dalteparin Thromboprophylaxis Associated With Reduced Risk of VTE in Cancer

Dalteparin Thromboprophylaxis Associated With Reduced Risk of VTE in Cancer

Thromboprophylaxis with dalteparin is associated with a non-significant decreased risk of venous thromboembolism (VTE).

XPO1 Inhibitor Represents New Treatment Paradigm in CLL, AML

XPO1 Inhibitor Represents New Treatment Paradigm in CLL, AML

KPT-8602 allows a prolonged frequent dosing schedule in animal models of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).

Venetoclax Plus Decitabine or Azacitidine Active, Safe in Elderly Treatment-Naïve Acute Leukemia

Venetoclax Plus Decitabine or Azacitidine Active, Safe in Elderly Treatment-Naïve Acute Leukemia

Combination therapy of venetoclax with decitabine or azacitidine demonstrated tolerable safety in acute myeloid leukemia (AML).

Spliceosome Modulators Could Be New Thereapeutic Targets in Myeloid Malignancies

Spliceosome Modulators Could Be New Thereapeutic Targets in Myeloid Malignancies

Genetic and pharmacologic evidence point to splicing factor mutant leukemias as being "preferentially sensitive to splicing modulation in vivo."

Adding Rituximab Improves EFS in CD20-Positive, Ph-Negative Acute Leukemia

Adding Rituximab Improves EFS in CD20-Positive, Ph-Negative Acute Leukemia

Adding rituximab to the pediatric-inspired GRAALL protocol improved event-free survival in acute lymphoblastic leukemia.

Midostaurin Prolongs Survival in Patients with Newly Diagnosed AML

Midostaurin Prolongs Survival in Patients with Newly Diagnosed AML

The addition of midostaurin to standard chemotherapy significantly improved survival in acute myeloid leukemia (AML).

Intensive Therapy Strategies in Older Patients With AML Remain Standard of Care

Intensive Therapy Strategies in Older Patients With AML Remain Standard of Care

Single-agent clofarabine is inferior to standard therapy in older patients with newly diagnosed acute myeloid leukemia (AML).

PD-L1, PD-L2 Alterations Linked to High Response, Durable Remission in Hodgkin Lymphoma

PD-L1, PD-L2 Alterations Linked to High Response, Durable Remission in Hodgkin Lymphoma

Research has confirmed "the importance of genetically defined PD-1 mediated immune evasion in classical Hodgkin lymphomas."

MRD Monitoring in Younger Patients With NPM1 Mutated AML Clinically Relevant

MRD Monitoring in Younger Patients With NPM1 Mutated AML Clinically Relevant

Researchers have confirmed 2 clinically relevant minimal residual disease checkpoints in younger patients with acute myeloid leukemia (AML).

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs